Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Paper by: Leon Caly, Julian D.Druce, Mike G.Catton, David A.Jans, Kylie M.Wagstaff

[Received 18 March 2020, Revised 27 March 2020, Accepted 29 March 2020, Available online 3 April 2020.]

Highlights

•

Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.

•

A single treatment able to effect ~5000-fold reduction in virus at 48 h in cell culture.

•

Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.

•

Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.

---------------------------------------------------------------------------

Read the full article here:  ScienceDirect

Also See: 

Ivermectin for Severe COVID-19 Management

Evaluation of the Effectiveness and Safety of Adding Ivermectin to Treatment in Severe COVID-19 Patients  (PDF Doc)

Ivermectin

Related:

FLCCC Alliance Story